The single-dose vaccine is being considered by an outside advisory committee to the U.S. Food and Drug Administration later this week, and emergency use authorization could come shortly afterward.
Nettles also said Johnson & Johnson expects to be able to ship nearly 4 million doses of its COVID-19 vaccine upon authorization in the U.S.
RICHARD NETTLES: Although we are cautious not to prejudge the outcome of the ongoing FDA review process, we believe that our single-dose vaccine will be a critical tool for fighting this global pandemic. 28 days after vaccination, the vaccine provided complete protection against COVID-19-related hospitalization and death.
The vaccine was 85% effective overall in preventing severe disease, including across countries with newly emerging variants. The vaccine was 72% effective in the United States at preventing moderate to severe disease. Based on these data, earlier this month, we saw emergency use authorization from the FDA. The FDA's advisory committee will meet later this week.
Assuming necessary regulatory approvals, we are ready to begin shipping immediately and deliver enough single doses by the end of March to enable the vaccination of more than 20 million Americans. Furthermore, we will meet our target to deliver 100 million single-dose vaccines to the United States during the first half of 2021.